FUSN
- Fusion Pharmaceuticals Inc.
()
Overview
Company Summary
Fusion Pharmaceuticals Inc. (FUSN) is a biopharmaceutical company that specializes in the development of targeted alpha therapies (TATs) for the treatment of various types of cancer. TATs are a novel class of cancer therapeutics that combine the specificity of antibodies with the potency of alpha radiation.
Fusion Pharmaceuticals uses a unique approach to selectively deliver alpha-emitting isotopes directly to cancer cells. This targeted approach aims to minimize damage to healthy tissues while maximizing the destruction of cancer cells. By attaching alpha-emitting isotopes to tumor-specific antibodies, Fusion Pharmaceuticals' TATs specifically bind to cancer cells, delivering a highly potent and localized radiation dose to the tumor site.
The company focuses on developing TATs for a range of cancer indications, including solid tumors and hematologic malignancies. Fusion Pharmaceuticals' pipeline includes multiple candidates in preclinical and clinical stages of development.
Through its innovative approach, Fusion Pharmaceuticals aims to address the limitations of traditional cancer treatments, such as chemotherapy and external-beam radiation therapy. The company's goal is to provide patients with more effective and targeted therapies while minimizing side effects and improving overall treatment outcomes.
In summary, Fusion Pharmaceuticals Inc. is a biopharmaceutical company that develops targeted alpha therapies for the treatment of cancer, aiming to combine the selectivity of antibodies with the potency of alpha radiation to improve patient outcomes.